MYOZ1

Across TCGA pan-cancer cohorts, MYOZ1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MYOZ1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MYOZ1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MYOZ1 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where MYOZ1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYOZ1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−2.036	<.001	9	view →
LUAD	Female	III,IV	−1.873	<.001	9	view →
HNSC	Male	II,III,IV	−1.644	<.001	8	view →
CCRCC	Male	III,IV	−0.974	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MYOZ1–LSCC

Open the LSCC breakdown →